GSK Avandia/insulin approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's Avandia (rosiglitazone) clears FDA Feb. 27 for use in combination with insulin, based on a 220-patient study showing no cardiovascular safety signal in type 2 diabetes patients. The approval comes two years after GSK received a new label warning about an increased risk of heart failure with the combo regimen. After the label update, the firm successfully lobbied FDA to require a similar revision to Lilly/Takeda's Actos (pioglitazone) labeling, which already carried an approval for use with insulin. GSK's challenge in promoting the new indication will be to reverse clinicians' current impressions about combo use of the thiazolidinedione and insuli
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.